Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity by Weickert, C S et al.
Schizophrenia-associated HapICE haplotype is
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Excitement and controversy have followed neuregulin (NRG1) since its discovery as a putative schizophrenia susceptibility
gene; however, the mechanism of action of the associated risk haplotype (HapICE) has not been identiﬁed, and speciﬁc genetic
variations, which may increase risk to schizophrenia have remained elusive. Using a postmortem brain cohort from 37
schizophrenia cases and 37 controls, we resequenced upstream of the type I–IV promoters, and the HapICE repeat regions in
intron 1. Relative abundance of seven NRG1 mRNA transcripts in the prefrontal cortex were determined and compared across
diagnostic and genotypic groups. We identiﬁed 26 novel DNA variants and showed an increased novel variant load in cases
compared with controls (v
2¼7.815; P¼0.05). The average nucleotide diversity (h¼10.0 10
 4) was approximately twofold
higher than that previously reported for BDNF, indicating that NRG1 may be particularly prone to genetic change. A greater
nucleotide diversity was observed in the HapICE linkage disequilibrium block in schizophrenia cases (h(case)¼13.2 10
 4;
h(control)¼10.0 10
 4). The speciﬁc HapICE risk haplotype was associated with increased type III mRNA (F¼3.76, P¼0.028),
which in turn, was correlated with an earlier age of onset (r¼ 0.343, P¼0.038). We found a novel intronic ﬁve-SNP haplotype
B730kb upstream of the type I promoter and determined that this region functions as transcriptional enhancer that is
suppressed bySRY. We propose that the HapICE risk haplotype increases expression ofthe most brain-abundant formof NRG1,
which in turn, elicits an earlier clinical presentation, thus providing a novel mechanism through which this genetic association
may increase risk of schizophrenia.
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Introduction
Neuregulin-1 (NRG1), a pluripotent regulator of neuro-
development,
1–5 has shown genetic association with the
diagnosis of schizophrenia in many but not all populations
from around the world,
6,7 implicating SNP polymorphisms
in both the 50 and 30 regions.
8,9 Meta-analysis of 22 studies
has demonstrated replication at the level of the haplotype but
not at the single SNP level,
7,10 and have highlighted
signiﬁcant between study heterogeneity, suggesting that
speciﬁc risk alleles are likely to vary across populations and
individuals.
Association of NRG1 genotypes with a variety of pheno-
types, including mRNA expression levels, brain volume, brain
activation and eye movements have been identiﬁed.
11–17
Furthermore, thehigh afﬁnitytyrosine kinasereceptor,ErbB4,
which partners with NRG1 to control neurodevelopment,
2,4,5
is also associated with schizophrenia at both genetic and
transcriptional levels.
18–22 Thus, at least two key components
of a neurodevelopmental signaling pathway have been
strongly implicated in the etiology of schizophrenia.
The mechanism by which variation in NRG1 and ErbB4
increases risk for schizophrenia is unknown. Available
evidence suggests that splice variant speciﬁc NRG1/ErbB4
overexpression
11,13,18,21,23 and hypersignaling of NRG1
24
may be involved, although some reports of reduced or
unchanged expression of NRG1 mRNA or protein (alpha
form) in the brain and serum also exist.
23,25,26 Speciﬁc mRNA
transcripts of NRG1
11,13,15,23 and ErbB4
18,19,21 are increased
in the frontal cortex and hippocampus of patients with
schizophrenia and variable NRG1 transcript expression has
been linked to promoter and intronic polymorphisms asso-
ciated with schizophrenia;
11,13,15 however, the increase in
cortical NRG1 type I mRNA
11,13 has not been replicated in an
independent Caucasian cohort
23 and the relationship of
mRNA changes to the haplotype associated with increased
risk of a clinical diagnosis of schizophrenia
6,8,27 has not been
deﬁned. In addition, previous postmortem genetic studies of
NRG1
11,13,15 have been conducted in cohorts of mixed ethnicity
(largely African American), withnoethnicmatching toaccount
for differences in genetic diversity across the populations.
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www.nature.com/tpIn this study, we ﬁrst characterized the nucleotide
diversity in promoter regions of NRG1 in postmortem brain
tissue of 37 controls and 37 patients with schizophrenia,
most of Australian Caucasian ethnicity. We then tested
whether DNA variants were in linkage disequilibrium
(LD) with the schizophrenia-associated risk haplotype
(HapICE)
8,27 and whether they were functional. Lastly, we
determined if differences in seven NRG1 mRNA transcripts
were evident in the frontal cortex of schizophrenia in
this independent postmortem cohort, and whether NRG1
gene variants are associated with variation in mRNA
expression.
Materials and methods
Human postmortem cohort and tissue extraction. Standard
protocols
28 were used to extract genomic DNA and total RNA
from the dorsolateral prefrontal cortex (DLPFC) of 74 fresh
frozen postmortem brains available from the Tissue Resource
Center, Sydney, Australia. The demographic characteristics,
tissue processing and quality screening for this cohort is
described elsewhere,
29 and ascertainment and exclusions are
described in brief in Supplementary Material. Case (n¼37)
and control samples (n¼37) were matched for age, brain pH,
RNA integrity, hemisphere, gender and postmortem interval
(Supplementary Table 1).
Detection of nucleotide variation in NRG1 putative
regulatory regions. To characterize the nucleotide diver-
sity in the alternative promoter regions of NRG1 in DNA from
the DLPFC of the human postmortem brain cohort, we
resequenced B3kb upstream of each transcription start site
of the type IV/II, type I and type III isoforms via Bigdye
terminator sequencing (Applied Biosystems, Melbourne,
Victoria, Australia) (Figure 1). In addition, we sequenced the
polymorphisms constituting the 5-SNP and 7-marker HapICE
risk haplotypes
8 (SNP8NRG221132, SNP8NRG221533,
SNP8NRG241930, SNP8NRG243177 and SNP8NRG433E1006,
plus microsatellite repeats 478B14-848 and 420M9-1395).
Further details of SNP calling and bioinformatic analysis are
provided in supplementary material.
Australian control cohort. To estimate the prevalence of a
novel 5-SNP haplotype in the Australian population, 128
control individuals ascertained through the National pre-
valence study of psychosis
30 were screened. Further details
are given in supplementary material.
Quantiﬁcation of NRG1 isoform expression. Relative
transcript levels were measured for each cDNA sample in
triplicate by real-time quantitative RT-PCR and normalized to
the geometric mean of four endogenous control genes, which
did not differ between diagnostic groups. Details on quan-
titative PCR probes, methods and quality control are given in
supplementary methods and Supplementary Table 2.
Functional characterization of genetic polymorphi-
sms. Luciferase assays were performed in HEK293 cells
using the Dual-Luciferase Reporter Assay System (Promega,
Sydney, New South Wales, Australia) as per manufacturers’
instructions. DNA ampliﬁed from individuals with either a
wild-type or novel 5-SNP haplotype was cloned upstream of
the ﬁreﬂy luciferase reporter gene in pGL3B. Transfection
efﬁciency was monitored and normalized by cotransfection
with renilla luciferase. As gene variants in the novel haplotype
were bioinformatically predicted to alter SRY transcription
factor-binding efﬁciency, full-length human SRY cDNA (kindly
donated by Prof. Andrew Sinclair) cloned into pcDNA4.1 was
used for cotransfection.
Electrophoretic mobility shift assays were conducted to
determine whether alternative alleles affected transcription
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Figure 1 Genomic structure and location of resequenced regions of human NRG1. (a) Human NRG1 is transcriptionally complex, with over 30 known mRNA splicing
isoformsthataremainlydrivenofffouralternativepromoters(I–IV)andtwominorpromoters(V–VI).Alternativeisoformsincludedifferentfunctionalproteindomains,withtype
III isoform containing two transmembrane domains (TMD) and a cysteine-rich domain (CRD). Proteolytic cleavage of type I and III isoforms produces a C-terminal fragment
(CTF)andN-terminalfragment(NTF)containingabioactiveEGFdomain.Downstreamprocessingbyg-secretaseprocessestheCTFtoreleasetheintracellulardomain(ICD)
that contains the CRD. The position of the schizophrenia-associated HapICE haplotype is shown in the upstream promoter region. (b) The relative locations and sizes of
resequenced regions are shown and the positions of SNP and microsatellite markers that constitute the HapICE haplotype are indicated.
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Translational Psychiatryfactor binding in vitro. Reaction conditions and protocols were
as described previously.
31
Statistical analysis. Statistical analyses were conducted
using Statistica software (StatSoft, 2000; Tulsa, OK, USA).
Both Pearson-product moment and Spearman rho corre-
lations were calculated for relationships between brain cohort
characteristics (demographic and clinical) and normalized
NRG1 mRNA expression. Effects of dichotomous variables
(gender and hemisphere) were examined by t-tests. Overall
tests of normalized mRNA expression differences and
genotype effects were analyzed by one-way and two-way
ANCOVAs, taking into account any signiﬁcantly correlated
demographic variables.
Results
SNP discovery from deep targeted resequencing. In
total, over 919kb of good quality DNA sequence was
available for SNP discovery (12.5kb per sample), gene-
rated from the DNA extracted from the DLPFC of 74 human
postmortem brains. From this sequence, 65 DNA variants
were identiﬁed (Supplementary Tables 3 and 6), including 26
variants, which had not previously been characterized
(dbSNP130; Supplementary Figure 1 and Supplementary
Table 5). The novel DNA variants were relatively rare (minor
allele frequency¼0.044±0.038), and twice as likely to be
found exclusively in schizophrenia cases as compared with
controls (11 vs 5 novel SNPs; Supplementary Table 3).The
novel DNA variants were more likely to be functional than
previously known SNPs—85% were predicted in silico to
alter putative transcription factor-binding sites, compared
with 65% of the previously characterized SNPs observed in
our sample. Furthermore, a signiﬁcantly higher number of
schizophrenia patients had at least one novel variant
compared with controls (n¼24 vs 14; w
2¼10.8, P¼0.001),
and the novel variant load in each individual was greater in
schizophrenia cases compared with controls (Fishers exact
test: w
2¼7.815; P¼0.05; Supplementary Figure 2).
Nucleotide diversity in NRG1 and relationship to
schizophrenia diagnosis and HapICE. Overall, the
promoter and intronic regions of NRG1 had an average
nucleotide diversity (y) of 10.0 10
 4 (Supplementary Table
3), which is higher than the average found in promoter and
intronic regions of BDNF (y¼6.0±2.0 10
 4)
32 and 75
other comparator genes (5.4±1.5 10
 4).
33 We found the
lowest relative nucleotide diversity in the proximal promoter
IV/II region (y¼11.1 10
 4) and the highest nucleotide
diversity around the HapICE microsatellite repeats in intron 1
(y¼26.8 10
 4 and 30.1 10
 4, respectively, for 478B14-
848 and 420M9-1395). A greater nucleotide diversity was
observed in cases compared with controls, which was largely
driven by differences in the HapICE LD block (Figure 2);
however, the majority of these novel variants occurred in
individuals not carrying the speciﬁc HapICE risk haplotype.
A cluster of ﬁve novel SNPs was identiﬁed in 4 of the
37 schizophrenia cases (frequency¼0.054), but none of
the 37 controls. These novel SNPs run as a haplotype in a
single LD block (NCBI build 36: 31643–31875kb) sur-
rounding the HapICE microsatellite repeats in intron 1. As
this novel 5-SNP haplotype was relatively common in our
cases, we further explored its frequency in peripheral blood
samples from an independent psychiatrically assessed
Australian control population and found it to be rare (1/256
chromosomes; frequency¼0.0039), and not brain speciﬁc.
Frequency comparisons of HapICE risk haplotype. To
determine the frequency of the HapICE risk haplotype in the
Australian postmortem cohort, genotypes were phased using
PLINK and haplotypes with the best posterior probability of
being correct were selected (mean P-value¼0.91±0.15).
Frequencies of the 5-SNP and 7-marker risk haplotypes were
comparable between our Australian cohort (5-SNP: 32.4%;
7-marker: 12.2%) and those reported in the Scottish and
Icelandic populations (5-SNP: 31.4 and 28.6%; 7-marker: 8.0
and 11.0%, respectively).
27 No signiﬁcant frequency distor-
tion of either haplotype was observed in cases compared
with controls (P40.844); however, this is likely because of
the limited statistical power of our postmortem cohort to
detect genetic associations.
Demographic factors and NRG1 mRNA expression. The
type IV and EGFa isoforms were at the limit of detection
because of their very low expression in the DLPFC, and
hence their quantiﬁcation was deemed unreliable. However,
because of the interest in the type IV isoform in the literature,
we included those results in Supplementary Material, but
caution must be used in any interpretation.
Signiﬁcant correlations with RNA integrity values were
observed for all isoforms excluding type I(Ig2) at the Po0.05
level, and signiﬁcant correlationswith brain pH were observed
for pan-NRG1, EGFb, type II and type III mRNA (Supplemen-
tary Table 4). In addition, signiﬁcant correlations with age and
postmortem interval were observed for pan-NRG1 mRNA,
and postmortem interval only for type I(Ig2). All statistical
comparisons included signiﬁcant demographic variables as
covariates in an ANCOVA test. No sex effects were observed
for any robustly expressed NRG1 isoform in the DLPFC.
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Figure 2 Nucleotide diversity in NRG1 regions comparing 37 controls (light
gray) with 37 schizophrenia patients (dark gray). The dashed line indicates the
average nucleotide diversity from non-coding regions of 75 other human genes
33 at
y¼5.4 10
 4. The regions that fall within the HapICE LD block are indicated.
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Translational PsychiatryNRG1 genotype and NRG1 isoform expression. To
determine if the HapICE haplotype affected the expression
of NRG1 mRNA, we tested the seven NRG1 transcripts
against copies of the risk haplotype. We found a signiﬁcant
main effect of the 5-SNP haplotype on type III isoform
expression (ANCOVA F(2,69)¼3.763, P¼0.028, Figure 3a),
suggesting an allele dose response of type III expression
with genetic risk. This effect was found in both cases and
controls, and no main effect of diagnosis or haplotype  
diagnosis was observed (P40.770). Hence, the LD block
marked by the HapICE risk haplotype may contain a long-
range enhancer of type III expression. There was no
signiﬁcant effect of HapICE risk haplotype on expression of
other NRG1 isoforms (data not shown).
Next,wedeterminedifanyindividualSNPsimpactedNRG1
transcript levels. Because of constraints of sample size and
statistical power, only SNPs with minor allele frequency of
X25% were assessed. On this basis 11 of the 65 detected
SNPs, including rs6994992 and rs7014762 that were pre-
viously reported to affect isoform expression,
13,15 were tested
for main effects of genotype plus genotype   disease
interactions.
Three individual HapICE SNPs showed signiﬁcant or
suggestive effects on type III isoform expression:
SNP8NRG221533 (F(2,68)¼3.148, P¼0.05); SNP8NRG241930
(F(2,66)¼3.647, P¼0.032); and SNP8NRG243177
(F(2,69)¼2.919, P¼0.061), with no genotype   diagnosis
interactions observed (P-values all 40.58). These SNPs lie in
a single LD block over 1Mb upstream of the type III promoter
and are consistent with the haplotype ﬁndings.
Although we did not observe a signiﬁcant effect of
rs7014762 genotype on type III expression (F(2,66)¼1.587,
P¼0.212), the effect was in the same direction as that
previously reported
15—where the minor allele predicts de-
creased type III expression (mean values for each genotype
group (n¼6, 30, 38) were 3.01±0.43, 3.77±0.19, 3.95±
0.116, respectively). Unlike the previous study,
15 we did not
detect a genotype   diagnosis interaction for rs7014762 and
type III mRNA (F(6,132)¼0.394, P¼0.676). Further explora-
tion of rs7014762 in the context of the HapICE haplotype
showed that the major (C) allele lies on the speciﬁc risk
haplotype (Supplementary Figure 3).
A second cluster of SNPs in intron 1 affected type II isoform
expression. Signiﬁcant genotype   diagnosis effects were
observed for four individual SNPs: rs13263989, rs13253310,
rs3802160 and rs36213229 (P-values all 0.01–0.05). Two of
those individual SNPs lie in a 77kb LD block (NCBI build 36:
31708–31785kb), which lies over 90kb downstream of the
type II promoter, consisting of SNPs rs13263989,
rs13253310, rs11785744, the 478B14-848 microsatellite risk
allele (14 repeats) and rs34150028. Individuals carrying the
haplotype CCC(14)G showed a signiﬁcant increase in type II
expression (F(1,65)¼4.051, P¼0.048; Figure 3b). It should
be noted that none of these ﬁndings would survive strict
Bonferroni correction (corrected P¼0.0023 for 21 tests, for
effects of 11 SNPs in three independent LD blocks on seven
transcripts).
Diagnosis and brain hemisphere effect on NRG1 splice
variant gene expression. We found no main effect of
diagnosis on any NRG1 isoform measured (all Fo2.0, all
P40.05). Most of the NRG1 isoforms did not show
hemispheric differences in expression, with the exception of
pan-NRG1 and EGFb mRNAs. For pan-NRG1, we observed
higher expression in the left as compared with the right
prefrontal cortex for both cases and controls (Po0.03). For
EGFb, we detected a signiﬁcant diagnosis by hemisphere
interaction (F(1,66)¼4.00, P¼0.049). Hemispheric asymmetry
in EGFb expression was observed in normal controls, where
the left hemisphere has 23% more EGFb mRNA as com-
pared with the right (P¼0.019). Individuals with schizo-
phrenia had signiﬁcantly less EGFb mRNA in the left
hemisphere as compared with controls (P¼0.040), thus
there appears to be a loss of the normal hemispheric
asymmetry in EGFb expression in the disease state
(Supplementary Figure 4).
Clinical factors and NRG1 mRNA expression. Clinical
factors including age of onset, duration of illness, smoking
habit, anti-depressant history, daily chlorpromazine
(antipsychotic) use, last chlorpromazine use and life-time
chlorpromazine levels were examined for their effect on
NRG1 mRNA. Age of onset was found to have signiﬁcant
correlation speciﬁcally with NRG1 type III isoform mRNA
Figure 3 The effectof the HapICEandintron 1 haplotypeson NRG1 isoformexpression.(a) TheHapICE5 SNP risk haplotypeGCGTGhas a signiﬁcant effecton typeIII
isoformexpression(ANCOVAF(2,69)¼3.763,P¼0.028;post-hocLSD:P¼0.013478or0.019014(for1or2copiescomparedwith0copies))withmeanexpressionvalues
(±s.e.) for individuals (n) with 0 copies (n¼34), 1 copy (n¼32) or 2 copies (n¼8) were 3.446±0.168, 4.048±0.173, 4.349±0.357, respectively. (b) The intron 1
haplotype CCC(14)G has a signiﬁcant effect on type II expression (ANCOVA F(1,65)¼4.051, P¼0.048), with mean expression values (±s.d.) for individuals (n) with 0
copies (n¼46) or 1 copy (n¼26) were 1.18±0.56 and 1.49±0.56, respectively. No homozygotes for the CCC(14)G haplotype were observed.
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Translational Psychiatrylevels (r¼ 0.343, P¼0.038; Figure 4), suggesting
increased expression of NRG1 type III isoform relates to an
earlier age of onset of schizophrenia in our Australian cohort.
Duration of illness was positively correlated with type II
mRNA (r¼0.341, P¼0.041), suggesting an upregulation of
type II mRNA may occur with disease progression. This
effect disappeared when corrected for age at death (r¼0.035,
P¼0.843) although age at death was only signiﬁcantly
correlated with type II expression in cases (r¼0.342,
P¼0.048) and not controls (r¼ 0.738, P¼0.669), indi-
cating that the age effect on type II expression may be
disease speciﬁc. No signiﬁcant correlations were found for
any other isoform and age of onset, duration of illness (partial
correlations with age at death), or with any measure of
antipsychotic exposure.
Functional characterization of the unique 5-SNP
haplotype in intron 1. Three of the novel SNPs that
formed the novel 5-SNP haplotype were predicted in silico
to reduce SRY transcription factor binding. To determine
whether the two microsatellite regions that contained these
novel SNPs could affect gene transcription, B1kb of
sequence surrounding each repeat was cloned into a
pGL3B expression vector, from both a wild-type control
individual and a schizophrenic individual, who carried the
novel 5-SNP haplotype. In HEK293 cells (derived from an XX
female), the wild-type 478B14-848 construct did not induce
luciferase expression over baseline, however, a ﬁvefold
induction of expression was observed with the 420M9-1395
construct irrespective of genotype, indicating this region acts
as a transcriptional enhancer (Figure 5). By cotransfecting
human SRY (encoded on the male Y chromosome), the
efﬁciency of the 420M9-1395 intronic region to drive
transcription was reduced by around 15% (Figure 5), and
the combination of both SRY and the novel haplotype further
reduced expression over wild type at a trend level of
signiﬁcance (t¼1.7675, df¼9, P¼0.055). Electrophoretic
mobility shift assays experiments demonstrated that the
minor allele of one novel variant in 420M9-1395 (1395_1)
showed reduced nuclear protein binding in comparison with
the wild-type allele (Supplementary Figure 5), showing a
direct effect of at least one of the novel DNA variants on
transcription factor-binding efﬁciency. This suggests that the
novel SNP haplotype may accentuate the ability of SRY to
downregulate transcriptional activity at this enhancer, at least
in this context.
Discussion
NRG1, ﬁrst identiﬁed as a schizophrenia susceptibility gene
by linkage studies, has a relatively common risk haplotype in
the 50 promoter region; however, the mechanism through
which this speciﬁc risk haplotype may increase susceptibility
tomentalillnessiscontroversial.Ourstudyhasshownthatthe
50 upstream regions ofNRG1 have a relatively highnucleotide
diversity as compared with the 50 regions of many other
human genes previously investigated,
32–34 placing NRG1 in
the top 15% of those investigated. This suggests that the
regulatory regions of NRG1 may be relatively unstable and a
hotspot for genetic change. Furthermore, people with schizo-
phreniademonstrateahighernovelvariantloadthan controls,
Figure 4 Age of onset at ﬁrst diagnosis in postmortem brain cohort. (a) Frequency plot of age distribution in the sample, with age of onset on the x axis and frequency on
the y axis. (b) Correlation of age of onset with NRG1 type III expression. Type III expression is presented on the y axis as the standardized residual from the regression
equation after accounting for the signiﬁcant demographic effects of pH and postmortem interval (PMI) on expression. The linear regression line showing a signiﬁcant
correlation (r¼ 0.343, P¼0.038) is shown (black line) along with the mean 95% conﬁdence intervals (black curved lines).
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reporter construct
Figure 5 NRG1intron1containsatranscriptionalenhancer,whichisrepressed
by the transcriptionfactor SRY. HEK293 cells were transfected with 300ng reporter
constructs containing B1kb of DNA spanning the 478B14-848 and 420M9-1395
HapICE repeats, human SRY was cotransfected at 300ng (þSRY(1:1)) and
900ng (þSRY(1:3)). The wild-type and schizophrenia-associated novel 5-SNP
haplotypes are represented by the light and dark gray bars, respectively. The
normalized average values from two triplicate experiments are given.
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Translational Psychiatryparticularly in the HapICE LD block; however, the high variant
load was not linked to the speciﬁc risk haplotype. Observa-
tionsofa higher mutationalloadmay ﬁtwithother mechanistic
studies that suggest the genomes of people who develop
schizophrenia are more susceptible to DNA damage or
mistakes in DNA repair.
35 Indeed a recent study, suggests
that rare de novo mutations were more common in schizo-
phrenia genomes.
36 However, as peripheral tissue samples
were not collected alongside the brain tissue used in this
study, we are unable to determine whether the high novel
variant load we observed in NRG1 in schizophrenia is brain
speciﬁc. The presence of the novel 5-SNP haplotype in DNA
from peripheral blood in an independent cohort implies a
germline rather than somatic origin for this particular
haplotype, nevertheless future studies sampling additional
tissue sources from individual patients would be beneﬁcial in
determining the mechanism of the increased nucleotide
diversity in NRG1.
Importantly, this study provides the ﬁrst demonstrated link
betweentheHapICEriskhaplotypeandincreasedNRG1type
III mRNA expression levels in the human frontal cortex. A
previous study linking rs7014762 genotype with type III
expression reported that the minor allele (designated T) was
associated with schizophrenia, and that the minor allele
resulted in a reduced expression of type III mRNA.
15 In
support of this ﬁnding, Nicodemus et al.
15 incorrectly stated
that the same minor allele was also overtransmitted in bipolar
disorder in the study by Georgieva et al.
37; whereas it appears
that it was the major allele that was overtransmitted. We show
the same direction of effect of the minor allele (designated A)
on type III expression, with reduced expression of minor allele
homozygotes compared with major allele homozygotes.
However, our data and that of others,
37 shows that it is the
major allele of rs7014762 that lies on the schizophrenia-
associated HapICE risk haplotype and the major allele that is
signiﬁcantly overtransmitted to bipolar patients.
37 Hence, we
propose a novel mechanism of risk for psychosis, whereby an
increase, rather than a decrease, in type III mRNA is linked to
NRG1 genetic risk. Consistent with this observation is that
increased type III mRNA levels correlate with an earlier age
of onset and hence a more severe phenotype. Interestingly,
a study by Papiol et al.
38 indicates an age of onset effect
of the ‘protective’ alleles at SNP8NRG221533 and
SNP8NRG243177, where homozygous individuals (TT and
CC, respectively) show a later age of onset. This is
conceptually consistent with our ﬁnding that the HapICE risk
alleles lead to an earlier age of onset, by increasing type III
expression.
Ourﬁndingraisestheneedtomorefullyunderstandtherole
of NRG1 type III, the most brain-abundant and functionally
unique form of NRG1. NRG1 type III acts in a contact-
dependant manner, is expressed higher in deeper cortical
layers and can be found on axons of projection neurons.
39,40
Furthermore, NRG1 type III is membrane bound and thought
to be uniquely capable of back signaling to the nucleus
by proteolytic processing and release of a transcriptionally
active intracytoplasmic domain that increases neuronal
survival.
41 We previously found evidence of increased
NRG1-intracytoplasmic domain domain in the DLPFC of
people with schizophrenia.
42 Recently, an amino-acid sub-
stitution within the intramembranous domain of NRG1 was
associated with schizophrenia
43 and this change abolishes
intracytoplasmic domain cleavage and leads to decreased
branching and growth of cortical neuronal dendrites.
3 Com-
monly employed NRG1 type III mouse models use a
heterozygous transmembrane domain knockout
8 or a
cystine-rich domain knockout,
44 both of which model a reduction
in type III NRG1 expression while maintaining expression of
the soluble isoforms. Our data, which links type III over-
expression with disease risk, suggests that a NRG1 type III
hypermorphic mouse
45 may help to elucidate the molecular
mechanismofNRG1-relateddiseaserisk.Furtherworkisalso
needed to clarify how increased type III mRNA may further be
linked to changes in protein levels, NRG1-intracytoplasmic
domain formation and cortical function.
Another unique ﬁnding of our study was the discovery of a
novel 5-SNP haplotype in intron 1 that was present in 10% of
cases with schizophrenia (4/37 individuals vs 0/37 controls).
This haplotype was detected in peripheral blood from one
Australian control from a wider population sample, indicating
that it is both rare, and may not be exclusive to the brain or
disease. However, without longitudinal follow-up of this
subject, we cannot rule out that this haplotype is unique to
schizophrenia, as some individuals can be diagnosed later in
life.
46 As this novel SNP haplotype was found in DNA derived
fromboth bloodandbrain,it islikelythatthesechangesdonot
reﬂect somatic changes; however, further studies comparing
genetic diversity across different tissue types from the same
individual are necessary to more directly address the issue of
how ubiquitous unique and rare variants in the NRG1 gene
promoter may be.
If this novel 5-SNP haplotype is causal, then it should show
direct functional effects. In support of this, the 420M9-1395
region—containing 3/5 novel SNPs—was a potent driver of
gene expression in vitro. Furthermore, we found that SRY, a
sox-like male speciﬁc transcription factor, was able to down-
regulate activity of the 420M9-1395 enhancer and that
repression was more extreme with the novel schizophrenia-
associated haplotype. Although we were not able to directly
linkthenovel5-SNPhaplotypetoNRG1isoformexpressionin
the brain because of the rarity of the haplotype, we did ﬁnd a
more common haplotype that spanned the 420M9-1395
enhancer region that signiﬁcantly decreased NRG1 type II
expression. Further examination of the transcriptional effects
of this enhancer may elucidate whether it is important in
driving dysregulation of NRG1 transcripts in certain indivi-
duals, particularly the increased type I and decreased type II
ratio, which has been reported previously.
11 In this study, we
did notﬁnd large changesin anyNRG1 isoform withdiagnosis
alone, however, it may be that heterogeneity in cause and
course of schizophrenia or laterality effects may contribute to
the difﬁculties in reproducing mRNA expression changes
across independent cohorts.
Postmortem studies such as this do not aim to establish
genetic association with increased risk for schizophrenia, but
rather aim to explore the link between risk haplotype and
changesin gene expression andmutational diversity. Thus an
intrinsic limitation of our study is the power of the cohort for
detecting signiﬁcant genetic effects, and hence the ﬁndings
presented herein should be considered preliminary and
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association of the 5-SNP HapICE risk haplotype in our cohort,
despite a similar frequency difference between cases and
controlsintheAustralian postmortem cohortand theIcelandic
population
8 (5.4% vs 7.0%, respectively). In addition, the high
nucleotide diversity observed here should be interpreted with
caution, as we have not surveyed the entire gene, and
have observed a relatively small number of chromosomes.
The signiﬁcance of this increased nucleotide diversity will
become apparent with forthcoming next-generation sequen-
cing studies in larger population-based cohorts. Although our
postmortem sample is limited to detect statistically signiﬁcant
differences at the genetic level, it is one of the larger ethnically
matched Caucasian postmortem brain studies published to
date.TheearlierstudiesofNicodemusetal.
15andLawetal.
13
used a cohort of mixed ethnicity: 44 schizophrenia cases
(55% African American; 45% Caucasian) and 88 controls
(60% African American; 28% Caucasian). The Hashimoto
et al.
11cohort was largely African American with 19 schizo-
phrenia cases (74% African American; 26% Caucasian) and
20 controls (85% African American, 15% Caucasian). The
Parlapani et al. study
23 used a European Caucasian cohort
thatincluded8controlsand11casesforBA10.Giventhehigh
genetic diversity in the African American genome as
compared with European Caucasians, it is possible that
genetic effects observed in the African American population
will not be replicated in Caucasians and vice versa.
Although there is still ongoing debate as to the robustness
of the genetic association implicating NRG1 as a schizo-
phrenia susceptibility gene, functionally NRG1/ErbB3 is
critical for multiple stages of Schwann cell development,
47–49
and its role in promoting the development of myelin forming
cells is now recognized to include oligodendrocytes. Not only
are NRG1 and various ErbB receptors expressed in oligo-
genic zones,
2,50 but NRG1 can induce the division
51 and/or
promote the differentiation of oligodendrocyte and neuronal
precursors in vitro.
52–55 In particular, cell speciﬁc overexpres-
sion of NRG1 type III leads to increased myelination in
mice,
45,56 although how this relates to ﬁndings in schizo-
phrenia, which shows deﬁcits in molecular markers of myelin
or disrupted integrity of white matter, is unclear.
Interestingly, the NRG1-ErbB4 pathway appears critical to
the proper development and migration of cortical inhibitory
interneurons.
2,4,5 Soluble NRG1 (types I and II) act as cortical
chemoattractants, whereas the membrane bound form (type
III) acts in a contact dependant way to help guide migration
along certain paths.
5 Once developing interneurons reach the
cortex, axons expressing NRG1 type III can contact post-
synaptic ErbB4 and regulate the formation of excitatory
synapses from pyramidal neurons onto inhibitory neuron
dendrites.
4 Cortical interneurons are consistently found to be
deﬁcient in the prefrontal cortex of people with schizophre-
nia
57 and are also abnormal in our cohort.
58,59 Furthermore,
NRG1-induced migration was found to be altered in lympho-
blasts from patients with schizophrenia.
60 More studies are
needed to link the pathology of interneuron migration,
differentiation and survival to abnormalities in NRG1 in the
brains of patients with schizophrenia.
Our ﬁndings offer further evidence that abnormal expres-
sion of NRG1 isoforms in DLPFC may be related to the
pathophysiology of schizophrenia. We suggest a novel
mechanism of risk, involving increased NRG1 type III
expression in schizophrenia. Furthermore, we suggest that
the mechanism by which sequence variation within NRG1
imparts risk to schizophrenia is not solely driven by one SNP,
but may relate more to diversity in the genetic neighborhood
and accumulation of nucleotide changes. This is fueled by our
observation that sequence variation within NRG1 is high and
varies even more in the disease state. The implications of our
results at the phenotypic level are unknown, but they are at
least conceptually consistent with evidence that schizophre-
niainvolvesgeneticabnormalitiesindevelopmental/plasticity-
related processes involving NRG1.
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